{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:14:59Z","timestamp":1772788499654,"version":"3.50.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.vaccine.2018.01.032","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T19:19:47Z","timestamp":1517512787000},"page":"1190-1202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Reduced pathogenicity of fructose-1,6-bisphosphatase deficient Leishmania donovani and its use as an attenuated strain to induce protective immunogenicity"],"prefix":"10.1016","volume":"36","author":[{"given":"Savita","family":"Saini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayan Kumar","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushmita","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruby","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Abhishek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudha","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bidyut","family":"Purkait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kislay Kumar","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.01.032_b0005","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/j.vaccine.2015.12.071","article-title":"Status of vaccine research and development of vaccines for leishmaniasis","volume":"34","author":"Gillespie","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.032_b0010","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-3156.2009.02306.x","article-title":"Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India","volume":"14","author":"Olliaro","year":"2009","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2018.01.032_b0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fimmu.2014.00134","article-title":"Live vaccination tactics: possible approaches for controlling visceral leishmaniasis","volume":"5","author":"Saljoughian","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0020","first-page":"455","article-title":"Genetically modified live attenuated parasites as vaccines for leishmaniasis","volume":"123","author":"Selvapandiyan","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2018.01.032_b0025","first-page":"240","article-title":"Characterization of Leishmania isolated from unhealed lesions caused by leishmanization","volume":"11","author":"Hosseini","year":"2005","journal-title":"East Mediterr Health J Rev Sante Mediterr Orient Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit"},{"key":"10.1016\/j.vaccine.2018.01.032_b0030","first-page":"377","article-title":"Effectiveness of leishmanization in the control of cutaneous leishmaniasis","volume":"76","author":"Nadim","year":"1983","journal-title":"Bull Soc Pathol Exot Filiales"},{"key":"10.1016\/j.vaccine.2018.01.032_b0035","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1016\/j.vaccine.2008.09.085","article-title":"First generation leishmaniasis vaccines: a review of field efficacy trials","volume":"26","author":"Noazin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.032_b0040","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1016\/j.vaccine.2009.05.084","article-title":"Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis","volume":"27","author":"Noazin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.032_b0045","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.01.032_b0050","doi-asserted-by":"crossref","first-page":"234ra56","DOI":"10.1126\/scitranslmed.3008222","article-title":"Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis","volume":"6","author":"Das","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2018.01.032_b0055","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0060","doi-asserted-by":"crossref","first-page":"290ra90","DOI":"10.1126\/scitranslmed.aaa3043","article-title":"A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates","volume":"7","author":"Oliveira","year":"2015","journal-title":"Sci Transl Med"},{"issue":"172","key":"10.1016\/j.vaccine.2018.01.032_b0065","first-page":"3793","article-title":"Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response","volume":"2004","author":"Uzonna","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.vaccine.2018.01.032_b0070","doi-asserted-by":"crossref","first-page":"25703","DOI":"10.1074\/jbc.M402794200","article-title":"Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania","volume":"279","author":"Selvapandiyan","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2018.01.032_b0075","first-page":"1","article-title":"An overview on Leishmania vaccines: A narrative review article","volume":"6","author":"Rezvan","year":"2015","journal-title":"Vet Res Forum Int Q J"},{"key":"10.1016\/j.vaccine.2018.01.032_b0080","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.vaccine.2014.02.055","article-title":"Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites","volume":"32","author":"Finney","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.032_b0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nature03188","article-title":"Genetically modified Plasmodium parasites as a protective experimental malaria vaccine","volume":"433","author":"Mueller","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.01.032_b0090","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.1073\/pnas.92.22.10267","article-title":"Development of a safe live Leishmania vaccine line by gene replacement","volume":"92","author":"Titus","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.01.032_b0095","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2005.05.045","article-title":"Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models","volume":"24","author":"Saravia","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.032_b0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.70.1.62-68.2002","article-title":"Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination","volume":"70","author":"Papadopoulou","year":"2002","journal-title":"Infect Immun"},{"issue":"179","key":"10.1016\/j.vaccine.2018.01.032_b0105","first-page":"3161","article-title":"SIR2-deficient Leishmania infantum induces a defined IFN-gamma\/IL-10 pattern that correlates with protection","volume":"2007","author":"Silvestre","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.vaccine.2018.01.032_b0110","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.vaccine.2013.01.048","article-title":"Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs","volume":"31","author":"Fiuza","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.032_b0115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.vaccine.2014.11.039","article-title":"Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum","volume":"33","author":"Fiuza","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.032_b0120","first-page":"423","article-title":"Leishmaniasis vaccine candidates for development: a global overview","volume":"123","author":"Khamesipour","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2018.01.032_b0125","doi-asserted-by":"crossref","first-page":"6372","DOI":"10.1128\/IAI.73.10.6372-6382.2005","article-title":"Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis","volume":"73","author":"Breton","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.01.032_b0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7555\/JBR.27.20120064","article-title":"Development of Leishmania vaccines: predicting the future from past and present experience","volume":"27","author":"Mutiso","year":"2013","journal-title":"J Biomed Res"},{"key":"10.1016\/j.vaccine.2018.01.032_b0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00005-008-0010-9","article-title":"Live attenuated Leishmania vaccines: a potential strategic alternative","volume":"56","author":"Silvestre","year":"2008","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.vaccine.2018.01.032_b0140","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrmicro2608","article-title":"Leishmaniasis: complexity at the host\u2013pathogen interface","volume":"9","author":"Kaye","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0145","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/iai.61.3.1069-1073.1993","article-title":"Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis","volume":"61","author":"Kemp","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.01.032_b0150","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1128\/iai.62.3.1058-1063.1994","article-title":"Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis","volume":"62","author":"Miralles","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.01.032_b0155","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/1521-4141(200003)30:3<834::AID-IMMU834>3.0.CO;2-9","article-title":"IL-12 gene-deficient C57BL\/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology","volume":"30","author":"Satoskar","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0160","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.it.2007.07.004","article-title":"Interleukin-10 and the pathogenesis of human visceral leishmaniasis","volume":"28","author":"Nyl\u00e9n","year":"2007","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0165","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20061141","article-title":"Splenic accumulation of IL-10 mRNA in T cells distinct from CD4 + CD25 + (Foxp3) regulatory T cells in human visceral leishmaniasis","volume":"204","author":"Nyl\u00e9n","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.01.032_b0170","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1084\/jem.194.10.1497","article-title":"The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure","volume":"194","author":"Belkaid","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.01.032_b0175","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1128\/IAI.70.11.6284-6293.2002","article-title":"Interleukin-10 (IL-10) in Experimental Visceral Leishmaniasis and IL-10 Receptor Blockade as Immunotherapy","volume":"70","author":"Murray","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.01.032_b0180","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1086\/376510","article-title":"Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis","volume":"188","author":"Murray","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.032_b0185","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/IAI.70.2.826-835.2002","article-title":"Intracellular survival of Leishmania major in neutrophil granulocytes after uptake in the absence of heat-labile serum factors","volume":"70","author":"Laufs","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.01.032_b0190","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.pt.2007.06.009","article-title":"Living in a phagolysosome; metabolism of Leishmania amastigotes","volume":"23","author":"McConville","year":"2007","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0195","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbrc.2004.09.212","article-title":"Novel motifs in amino acid permease genes from Leishmania","volume":"325","author":"Akerman","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2018.01.032_b0200","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1073\/pnas.0509196103","article-title":"Virulence of Leishmania major in macrophages and mice requires the gluconeogenic enzyme fructose-1,6-bisphosphatase","volume":"103","author":"Naderer","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.01.032_b0205","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0166-6851(03)00173-7","article-title":"Pentose phosphate metabolism in Leishmania mexicana","volume":"130","author":"Maugeri","year":"2003","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0210","doi-asserted-by":"crossref","first-page":"32989","DOI":"10.1074\/jbc.M114.569434","article-title":"Gluconeogenesis in Leishmania mexicana: contribution of glycerol kinase, phosphoenolpyruvate carboxykinase, and pyruvate phosphate dikinase","volume":"289","author":"Rodriguez-Contreras","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2018.01.032_b0215","doi-asserted-by":"crossref","DOI":"10.1111\/mmi.13534","article-title":"Glucose deprivation induced upregulation of phosphoenolpyruvate carboxykinase modulates virulence in Leishmania donovani","author":"Saini","year":"2016","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0220","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1110289","article-title":"The Trypanosoma cruzi proteome","volume":"309","author":"Atwood","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.01.032_b0225","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.nu.11.070191.002341","article-title":"Hepatic gluconeogenesis\/glycolysis: regulation and structure\/function relationships of substrate cycle enzymes","volume":"11","author":"Pilkis","year":"1991","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.vaccine.2018.01.032_b0230","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1074\/jbc.273.6.3381","article-title":"In Vitro Reconstitution of Glucose-induced Targeting of Fructose-1,6-bisphosphatase into the Vacuole in Semi-intact Yeast Cells","volume":"273","author":"Shieh","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2018.01.032_b0235","first-page":"1084","article-title":"Stable transfection of the human parasite Leishmania major delineates a 30-kilobase region sufficient for extrachromosomal replication and expression","volume":"10","author":"Kapler","year":"1990","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0240","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1128\/JB.186.17.5799-5807.2004","article-title":"Genetic evidence identifying the true gluconeogenic fructose-1,6-bisphosphatase in Thermococcus kodakaraensis and other hyperthermophiles","volume":"186","author":"Sato","year":"2004","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0245","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1128\/AAC.49.11.4474-4484.2005","article-title":"Photodynamic sensitization of leishmania amazonensis in both extracellular and intracellular stages with aluminum phthalocyanine chloride for photolysis in vitro","volume":"49","author":"Dutta","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2018.01.032_b0250","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2958.2010.07230.x","article-title":"Screening Leishmania donovani-specific genes required for visceral infection","volume":"77","author":"Zhang","year":"2010","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0255","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1128\/AAC.39.9.2167","article-title":"Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice","volume":"39","author":"Buffet","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2018.01.032_b0260","first-page":"2027","article-title":"Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor","volume":"20","author":"Browne","year":"2006","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0265","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/icb.2011.80","article-title":"TGF-\u03b21 re-programs TLR4 signaling in L. donovani infection: enhancement of SHP-1 and ubiquitin-editing enzyme A20","volume":"90","author":"Das","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0270","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/IAI.69.11.6588-6596.2001","article-title":"Dual role of the Leishmania major ribosomal protein S3a homologue in regulation of T- and B-cell activation","volume":"69","author":"Cordeiro-Da-Silva","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.01.032_b0275","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/iai.33.2.498-500.1981","article-title":"Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection","volume":"33","author":"Carvalho","year":"1981","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.01.032_b0280","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0014-4894(82)90049-2","article-title":"Leishmania mexicana: energy metabolism of amastigotes and promastigotes","volume":"54","author":"Hart","year":"1982","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0285","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0165-2478(03)00021-X","article-title":"Infection pattern and immune response in the spleen and liver of BALB\/c mice intracardially infected with Leishmania donovani amastigotes","volume":"86","author":"Mukherjee","year":"2003","journal-title":"Immunol Lett"},{"issue":"143","key":"10.1016\/j.vaccine.2018.01.032_b0290","first-page":"266","article-title":"Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H\/HeN mice to infection with Leishmania major","volume":"1989","author":"Belosevic","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.vaccine.2018.01.032_b0295","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20070663","article-title":"Phenotypic and functional features of human Th17 cells","volume":"204","author":"Annunziato","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.01.032_b0300","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0952-7915(93)90033-O","article-title":"T-cell and cytokine responses in leishmaniasis","volume":"5","author":"Reed","year":"1993","journal-title":"Curr Opin Immunol"},{"issue":"146","key":"10.1016\/j.vaccine.2018.01.032_b0305","first-page":"3444","article-title":"IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells","volume":"1991","author":"Fiorentino","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.vaccine.2018.01.032_b0310","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1002\/1521-4141(2001010)31:10<2848::AID-IMMU2848>3.0.CO;2-T","article-title":"IL-10 mediates susceptibility to Leishmania donovani infection","volume":"31","author":"Murphy","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.01.032_b0315","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"issue":"175","key":"10.1016\/j.vaccine.2018.01.032_b0320","first-page":"2517","article-title":"IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection","volume":"2005","author":"Stober","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.vaccine.2018.01.032_b0325","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1084\/jem.189.4.741","article-title":"Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani","volume":"189","author":"Murray","year":"1999","journal-title":"J Exp Med"},{"issue":"176","key":"10.1016\/j.vaccine.2018.01.032_b0330","first-page":"5519","article-title":"Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen","volume":"2006","author":"Perez","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.vaccine.2018.01.032_b0335","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4269\/ajtmh.1996.54.486","article-title":"Nitric oxide production in murine leishmaniasis: correlation of progressive infection with increasing systemic synthesis of nitric oxide","volume":"54","author":"Evans","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.01.032_b0340","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.179.4.1367","article-title":"CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major","volume":"179","author":"Wang","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.01.032_b0345","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2174\/1566524043360212","article-title":"Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis","volume":"4","author":"Ravindran","year":"2004","journal-title":"Curr Mol Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:24:02Z","timestamp":1759400642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18300677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0264410X18300677"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced pathogenicity of fructose-1,6-bisphosphatase deficient Leishmania donovani and its use as an attenuated strain to induce protective immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}